98%
921
2 minutes
20
Torque teno virus (TTV) has been proposed as a surrogate biomarker of T-cell function in allogeneic-haematopoietic-stem-cell transplantation (allo-HSCT). Conflicting data exists regarding the value of TTV to assess the degree of immunosuppression. The aim of the present study was to investigate the correlation between TTV viral load and immune function. Using samples from a prospective cohort composed of healthy-volunteers (HV) and allo-HSCT recipients at 6 months post-transplantation, we assessed the correlation between TTV viraemia and immune cell counts or T-cell proliferation capacity post-phytohaemagglutinin stimulation. TTV viraemia was detected in 68% of HV ( = 80) and 100% of allo-HSCT recipients ( = 41; < 0.001); it was significantly higher in allo-HSCT recipients (3.9 vs. 2.1 Log copies/mL, < 0.001). There was no correlation between T-cell function and CD3T-cell count (rho: 0.002) suggesting that T-cell count can normalise without full functional recovery. Furthermore, no significant correlation was observed between TTV viraemia and absolute total/subset lymphocyte counts (rho: <0.13). The highest correlation was observed between TTV viral load and T-cell proliferation capacity (rho: -0.39). We therefore report an inverse correlation between T-cell function and TTV viraemia that is independent of T-cell count. Monitoring of TTV viraemia could be a fast suitable option to objectively assess the competence of immune function in at-risk populations.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7696489 | PMC |
http://dx.doi.org/10.3390/v12111292 | DOI Listing |
Int J Hematol
September 2025
Department of Hematology and Oncology, Asahikawa Red Cross Hospital, 1-1 Akebono-Cho, Asahikawa, Hokkaido, Japan.
Introduction: Allogeneic hematopoietic stem-cell transplantation (allo-HSCT) requires reliable vascular access for medication, transfusion, and blood sampling, which often involves painful venipuncture. This prospective study evaluated a novel dual peripherally inserted central venous catheter (PICC) technique to reduce venipuncture frequency in allo-HSCT recipients.
Methods: The study enrolled 29 allo-HSCT recipients.
Transplant Cell Ther
September 2025
Department of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine); Hangzhou, China; The First School of Clinical Medicine, Zhejiang Chinese Medical University; Hangzhou, China. Electronic address: szyyblood@1
Aplastic anemia (AA) is a bone marrow failure disorder treated with allogeneic hematopoietic stem cell transplantation (allo-HSCT). Despite improvements in conditioning regimens and GVHD prophylaxis, graft failure and GVHD remain critical challenges. This study compared the efficacy of mesenchymal stem cells (MSCs) and umbilical cord blood cells (UCBs) as adjunctive therapies in 184 AA patients undergoing allo-HSCT.
View Article and Find Full Text PDFInt J Hematol
September 2025
Department of Hematology, Graduate School of Medicine, Kyoto University, 54 Kawaharacho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.
We retrospectively analyzed the effectiveness of posaconazole (tablet and infusion formulations) and its correlation with blood concentration in preventing invasive fungal infections (IFIs) in 360 patients who underwent allogeneic hematopoietic stem cell transplant (allo-HSCT) between 2010 and 2023. A total of 61 patients received posaconazole, 102 received micafungin, and 197 received fluconazole for primary prophylaxis. By day 100 post-transplant, the cumulative incidence of IFIs was significantly lower with posaconazole (5.
View Article and Find Full Text PDFClin Transplant
September 2025
Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Background: Graft-versus-host disease (GvHD) remains a major barrier to long-term survival after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Although calcineurin inhibitors (CNIs) are the cornerstone of GvHD prophylaxis, some patients cannot tolerate them, creating a critical need for alternative strategies.
Objective: To evaluate the efficacy and safety of sirolimus plus low-exposure CNIs as an alternative GvHD prophylaxis in CNI-intolerant recipients undergoing allo-HSCT.
Transplant Cell Ther
August 2025
Department of Hematology and Rheumatology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.
Background: Adult T-cell leukemia/lymphoma (ATL) is an aggressive malignancy with a poor prognosis. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative option but has been limited in older patients due to toxicity risks. With Japan's aging population and evolving treatment options, reassessing allo-HSCT in patients aged ≥65 is essential.
View Article and Find Full Text PDF